
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc. has demonstrated a robust growth trajectory with a year-over-year revenue increase that beat consensus expectations, supported by strategic initiatives aimed at enhancing Light Adjustable Lens (LAL) volumes. The company is well-positioned to achieve double-digit growth, fueled by an expanding installed base of LDDs and increased utilization rates. Furthermore, management's guidance for improved gross margins, raised to 76-77%, indicates a positive outlook for profitability alongside a commitment to controlled operating expenses.
Bears say
RxSight Inc. has experienced a decline in key financial metrics, with a 14% year-over-year decrease in revenue to $30.3 million and a significant drop in the monthly utilization of light adjustable lenses (LALs), falling to 8.0 per laser delivery device (LDD) from 10.1 a year earlier. Furthermore, LDD placements in the second quarter of 2025 were substantially lower than expected, down 68% year-over-year and 38% quarter-over-quarter, leading to a projected total of only 150 placements for the year. The company faces multiple risks, including limited adoption due to the requirement for capital equipment, disappointing commercial execution, increasing competition in the intraocular lens market, and the potential necessity for dilutive financing.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares